ROIVANT SCIENCES LTD. is a pharmaceutical company that builds subsidiary biotech and health technology companies.[1][2] Roivant's initial strategy of in-licensing late-stage drug candidates through subsidiaries was later expanded to develop earlier stage drug candidates and other healthcare technologies through those same subsidiaries.[3]

The company was founded in 2014 by Vivek Ramaswamy.[4] The company's leadership includes: Mayukh Sukhatme, Matthew Gline, Myrtle Potter,[5] Frank Torti,[6] Adele Gulfo, Sam Azoulay,[7] Ben Zimmer and Allen Waxman.[8]

In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries.[9]


Subsidiaries

The company's subsidiaries include:

-   Axovant Sciences was founded in 2014, and as of 2016 was developing intepirdine as an add-on treatment for Alzheimer's disease and nelotanserin for Lewy body dementia.[10][11] Biotech analysts John Carroll of _FierceBiotech_ and Adam Feuerstein of _The Street_ noted that the IPO was overvalued based on the inexperience of the CEO and the low quality of its lead product, describing it as something that "GSK sold for lunch money".[12][13][14] In September 2017 the company announced that its Phase III trial of intepirdine as an adjuvant to donepezil had failed to show any improvement over donepezil alone.[15][16] In June 2018, the company licensed worldwide rights to AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease, from Oxford BioMedica.[17][18] In July 2018, it licensed the rights to AXO-AAV-OPMD, an investigational gene therapy for oculopharyngeal muscular dystrophy, from Benitec Biopharma.[19][20]
-   Myovant was founded in partnership with Takeda to address women’s health and endocrine disease treatments, is developing therapies for uterine fibroids, endometriosis, prostate cancer and female infertility.[21] Myovant has a license in some territories for relugolix.[22]
-   Enzyvant was founded to develop therapies for rare diseases.[23][24] One of its treatments is human acid ceramidase being developed as treatment for Farber disease.[25] Another was licensed from Duke University in 2017 and is a potential treatment for a kind of DiGeorge syndrome; the treatment is thymus tissue that is harvested, treated, and implanted in a person with the condition.[26]
-   Dermavant Sciences, founded to develop drugs for the immuno-dermatology skin diseases psoriasis and atopic dermatitis, as well as vitiligo, primary focal hyperhidrosis, and acne.[27]
-   Urovant was formed in 2017 to complete development of vibegron, a drug candidate for overactive bladder that Merck had developed through a Phase III trial before partnering with Kyorin. Urovant later licensed vibegron from Merck.[28]
-   Sinovant Sciences launched in 2018 to develop treatments for China’s medical issues. The company started with 11 investigational biopharmaceutical products for Greater China and other Asian markets.[29]
-   Immunovant was launched in July 2018.[30]
-   Metavant focuses on cardiometabolic disease and has rights to LGD-6972, a glucagon receptor antagonist, and imeglimin.[31]
-   Genevant Sciences was created to work on RNA-based therapeutics.[32]
-   Datavant was created to break down silos between healthcare datasets.[33]
-   Respivant Sciences was created to research serious respiratory diseases.[34]
-   Aruvant Sciences, launched in partnership with the Cincinnati Children’s Hospital Medical Center, was established to develop gene therapies for hematological diseases.[35]
-   Altavant Sciences was formed in June 2018 to develop a treatment for pulmonary arterial hypertension.[36]
-   Primavant Ltd. registered by Roivant Sciences Ltd. at Clarendon House 2 Church Street, Hamilton, Bermuda HM 11 with registration number 54243 leads to the possibility of a new subsidiary in the works.


Funding


References


External links

-   Official website

Category:Pharmaceutical companies established in 2014 Category:Life sciences industry Category:Multinational companies

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12] |url=http://www.fiercebiotech.com/biotech/why-axovant-s-315m-ipo-bonanza-should-scare-hell-out-of-you%7Cwork=FierceBiotech%7Cdate=June 11, 2015|language=en}}

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]  BioSpace|work=BioSpace|access-date=2018-11-08|language=en-US}}

[30]

[31]

[32]

[33]

[34]

[35]

[36]